1. Home
  2. ATNM vs JMM Comparison

ATNM vs JMM Comparison

Compare ATNM & JMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • JMM
  • Stock Information
  • Founded
  • ATNM 2000
  • JMM 1988
  • Country
  • ATNM United States
  • JMM United States
  • Employees
  • ATNM N/A
  • JMM N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • JMM Trusts Except Educational Religious and Charitable
  • Sector
  • ATNM Health Care
  • JMM Finance
  • Exchange
  • ATNM Nasdaq
  • JMM Nasdaq
  • Market Cap
  • ATNM 50.2M
  • JMM 59.8M
  • IPO Year
  • ATNM N/A
  • JMM N/A
  • Fundamental
  • Price
  • ATNM $1.51
  • JMM $6.30
  • Analyst Decision
  • ATNM Strong Buy
  • JMM
  • Analyst Count
  • ATNM 2
  • JMM 0
  • Target Price
  • ATNM $4.50
  • JMM N/A
  • AVG Volume (30 Days)
  • ATNM 160.4K
  • JMM 16.1K
  • Earning Date
  • ATNM 11-13-2025
  • JMM 01-01-0001
  • Dividend Yield
  • ATNM N/A
  • JMM 5.44%
  • EPS Growth
  • ATNM N/A
  • JMM N/A
  • EPS
  • ATNM N/A
  • JMM N/A
  • Revenue
  • ATNM N/A
  • JMM N/A
  • Revenue This Year
  • ATNM N/A
  • JMM N/A
  • Revenue Next Year
  • ATNM N/A
  • JMM N/A
  • P/E Ratio
  • ATNM N/A
  • JMM N/A
  • Revenue Growth
  • ATNM N/A
  • JMM N/A
  • 52 Week Low
  • ATNM $1.03
  • JMM $5.29
  • 52 Week High
  • ATNM $2.41
  • JMM $6.10
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 43.91
  • JMM 49.10
  • Support Level
  • ATNM $1.47
  • JMM $6.18
  • Resistance Level
  • ATNM $1.59
  • JMM $6.38
  • Average True Range (ATR)
  • ATNM 0.08
  • JMM 0.08
  • MACD
  • ATNM -0.00
  • JMM -0.01
  • Stochastic Oscillator
  • ATNM 28.95
  • JMM 57.14

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About JMM Nuveen Multi-Market Income Fund (MA)

Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.

Share on Social Networks: